Invention Grant
US08349318B2 Use of specifically engineered enzymes to enhance the efficacy of prodrugs
失效
使用特异性工程化的酶来增强前药的功效
- Patent Title: Use of specifically engineered enzymes to enhance the efficacy of prodrugs
- Patent Title (中): 使用特异性工程化的酶来增强前药的功效
-
Application No.: US12993660Application Date: 2009-05-18
-
Publication No.: US08349318B2Publication Date: 2013-01-08
- Inventor: Arnon Lavie , Manfred Konrad
- Applicant: Arnon Lavie , Manfred Konrad
- Applicant Address: US IL Urbana
- Assignee: The Board of Trustees of the University of Illinois
- Current Assignee: The Board of Trustees of the University of Illinois
- Current Assignee Address: US IL Urbana
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- International Application: PCT/US2009/044318 WO 20090518
- International Announcement: WO2009/143048 WO 20091126
- Main IPC: A61K38/54
- IPC: A61K38/54 ; A61K39/00 ; G01N33/53 ; C12P21/06 ; C12N9/96 ; C07H21/04
Abstract:
The invention provides methods for enhancing efficiency of prodrugs by specifically engineered enzymes with altered or enhanced activity and broader substrate specificity towards nucleoside analogs used in cancer chemotherapy, and delivering the enzymes to specific target cells in a patient. The invention also provides modified deoxycytidine kinase (dCK) mutants with such enhanced activities. Furthermore, the invention provides antibody-conjugated enzymes, pharmaceutical composition and kit containing the same, that can be specifically delivered to tumor cells.
Public/Granted literature
- US20110129470A1 USE OF SPECIFICALLY ENGINEERED ENZYMES TO ENHANCE THE EFFICACY OF PRODRUGS Public/Granted day:2011-06-02
Information query
IPC分类:
